Citigroup
ACET icon

Citigroup’s Adicet Bio ACET Stock Holding History

Citigroup’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$134 – 6012
2025
Q3 		$134 Sell
10
-34
-77% -$401 ﹤0.01% 5790
2025
Q2 		$432 Sell
44
-99
-69% -$1.04K ﹤0.01% 5449
2025
Q1 		$1.73K Buy
143
+128
+853% +$1.83K ﹤0.01% 5349
2024
Q4 		$232 Sell
15
-9
-38% -$170 ﹤0.01% 5657
2024
Q3 		$553 Sell
24
-470
-95% -$10.5K ﹤0.01% 5476
2024
Q2 		$9.56K Sell
494
-184
-27% -$4.93K ﹤0.01% 5154
2024
Q1 		$25.5K Buy
678
+336
+98% +$13.9K ﹤0.01% 4956
2023
Q4 		$10.4K Buy
342
+293
+598% +$6.39K ﹤0.01% 5188
2023
Q3 		$1.08K Sell
49
-1,598
-97% -$56.4K ﹤0.01% 5085
2023
Q2 		$64K Buy
1,647
+1,586
+2,600% +$140K ﹤0.01% 4500
2023
Q1 		$5.59K Sell
61
-4,942
-99% -$620K ﹤0.01% 4915
2022
Q4 		$716K Sell
5,003
-2,504
-33% -$625K ﹤0.01% 2913
2022
Q3 		$1.71M Buy
7,507
+7,311
+3,730% +$1.86M ﹤0.01% 2270
2022
Q2 		$46K Buy
196
+74
+61% +$16.2K ﹤0.01% 4569
2022
Q1 		$39K Sell
122
-271
-69% -$62.3K ﹤0.01% 4831
2021
Q4 		$110K Buy
393
+128
+48% +$22K ﹤0.01% 4681
2021
Q3 		$33K Buy
265
+82
+45% +$10.2K ﹤0.01% 4977
2021
Q2 		$30K Sell
183
-548
-75% -$112K ﹤0.01% 5075
2021
Q1 		$153K Buy
731
+7
+1% +$1.61K ﹤0.01% 4155
2020
Q4 		$163K Buy
724
+705
+3,711% +$144K ﹤0.01% 5142
2020
Q3 		$4K Sell
19
-1
-5% -$253 ﹤0.01% 7089
2020
Q2 		$5K Sell
20
-38
-66% -$7.47K ﹤0.01% 7250
2020
Q1 		$7K Buy
58
+5
+9% +$742 ﹤0.01% 7148
2019
Q4 		$9K Buy
53
+41
+342% +$20.8K ﹤0.01% 7228
2019
Q3 		$12K Sell
12
-30
-71% -$33.5K ﹤0.01% 6975
2019
Q2 		$48K Buy
42
+21
+100% +$19K ﹤0.01% 6514
2019
Q1 		$16K Buy
21
+8
+62% +$7.27K ﹤0.01% 7053
2018
Q4 		$12K Sell
13
-6
-32% -$7.9K ﹤0.01% 7080
2018
Q3 		$32K Buy
19
+7
+58% +$9.13K ﹤0.01% 6846
2018
Q2 		$12K Hold
12
– – ﹤0.01% 7108
2018
Q1 		$13K Buy
+12
New +$22K ﹤0.01% 6931

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Citigroup's ACET Position: Q4 2025 in Review

Citigroup sold out of Adicet Bio (ACET) in Q4 2025, closing a stake of 10 shares — an estimated $134 sold.

Citigroup first reported a position in ACET in Q1 2018 and held it in 31 quarters. The position peaked at $1.71M in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q4 2025.

  • Citigroup reported no remaining Adicet Bio position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 10 Adicet Bio shares in Q4 2025, an estimated $134.
  • Citigroup first reported a position in Adicet Bio in Q1 2018 and held it in 31 quarters.
  • Citigroup's Adicet Bio position peaked at $1.71M in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.